LLY changes
Pick any two versions below to diff them.
- Price
- $1354.00 → $1437.29(+6.2%)
- Recent events
- added: Nov 9, 2026: Lilly said that Foundayo met its main goal in the ATTAIN-OSA Phase 3 program in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight. At 52 weeks, it reduced breathing interruptions during sleep by up to 44% on average. Lilly plans to submit Foundayo to the FDA for sleep apnea by the end of 2026. Nov 6, 2026: Lilly and Hims & Hers agreed that patients who get a prescription on the Hims & Hers platform can buy Zepbound and Foundayo at Lilly's self-pay prices, from $149 a month for Foundayo and $299 a month for Zepbound. Oct 29, 2026: Lilly reported Q3 2026 results. Revenue rose 39% to $24.4 billion, with volume up 53% and realized prices down 15%. Revenue included about $900 million of one-time benefits. EPS was $7.22 reported and $7.48 non-GAAP, after acquired IPR&D charges of $4.57 per share. Lilly raised its 2026 guidance to revenue of $91 billion to $92 billion and non-GAAP EPS of $35.00 to $36.00. The FDA approved Mounjaro to lower cardiovascular risk in type 2 diabetes and Onswik, a once-weekly insulin. Retatrutide beat Ozempic in a head-to-head trial in type 2 diabetes. After the quarter, Lilly completed its purchase of Merida Biosciences. added: Oct 27, 2026: Lilly said that Patrik Jonsson, the president of Lilly International, will retire at the end of 2026. From January 1, 2027, Ilya Yuffa will lead sales worldwide as president of Lilly Global Markets, and Laura Steele will become president of Lilly USA. Sep 11, 2026: Lilly completed its purchase of AtaiBeckley, which develops BPL-003, a nasal spray for treatment-resistant depression. Lilly paid $6.75 per share in cash, plus up to $2.50 per share more if development and approval goals are met. Aug 5, 2026: Lilly reported Q2 2026 results. Revenue rose 48% to $23.0 billion, and EPS was $7.94 reported and $8.38 non-GAAP, after acquired IPR&D charges of $3.03 per share. Lilly raised its 2026 revenue guidance to $85 billion to $87 billion. It said that the retatrutide data are complete for obesity, sleep apnea and knee osteoarthritis pain, and that it plans to submit retatrutide to the FDA in Q1 2027. It completed the purchases of Orna, Ajax, Centessa and Kelonia, and it committed $4.5 billion more to its Indiana sites. Jul added: 23, 2026: Retatrutide met its main goals in two more Phase 3 trials. Adults with obesity and type 2 diabetes lost up to 20.8% of their weight at 80 weeks, and adults with severe obesity and heart disease lost up to 22.6%. Lilly said that it has the data to submit retatrutide to the FDA in Q1 2027. Jul 1, 2026: Medicare beneficiaries got access to discounted Lilly obesity medicines under the Medicare GLP-1 Bridge program, which runs to December 31, 2027. May 20, 2026: Lilly completed a $9.0 billion notes offering, with floating rate notes due 2028 and 2029 and fixed rate notes. It used the money to repay commercial paper and to pay part of the Centessa and Kelonia purchases. Apr 1, 2026: The FDA approved Foundayo (orforglipron), a daily GLP-1 pill for obesity that patients can take at any time without food or water limits. Lilly started to ship it on April 6, 2026. Feb 4, 2026: Lilly reported Q4 2025 results. Revenue rose 43% to $19.3 billion, and EPS was $7.39 reported and $7.54 non-GAAP. It gave 2026 guidance of revenue of $80 billion to $83 billion and non-GAAP EPS of $33.50 to $35.00. Nov 6, 2025: Lilly agreed with the U.S. government to expand access to obesity medicines at lower prices, including for Medicare and Medicaid patients.